Yamo Pharmaceuticals is developing L1-79, an investigational compound for the treatment of autism.
L1-79 is the first new investigational drug that appears to have the potential to improve the core symptoms and behavior in people with autism. L1-79 is based on a drug already approved by the U.S. Food and Drug Administration (FDA). L1-79 has so far been administered to over 40 people and, unlike other drugs approved for the treatment of autism, it has been well-tolerated. The preliminary data generated has shown that in certain patients, L1-79 has improved commonly used and accepted measures of:
- speech and communication
But we need to learn more and we need your help!
Yamo Pharmaceuticals is actively seeking to identify participants for future clinical studies of L1-79. Clinical studies are needed to prove that drugs are effective, safe to use and approved for use by the people who need them.
Please take a moment to fill out the form below. If the person qualifies for a future study based on the answers to the eligibility questions, our study director will contact you shortly with more details.